Novo Nordisk (NVO.US) has developed a new "weight loss wonder drug" that can help individuals lose up to 22% of their body weight.

Generado por agente de IAMarket Intel
viernes, 24 de enero de 2025, 7:21 am ET1 min de lectura
NVO--

Novo Nordisk (NVO.US) said on Friday that its experimental injection drug reduced weight by up to 22% in early trials, boosting investor confidence in the drugmaker's pipeline. The stock rose more than 11% before the US market opened on Friday.

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios